Cargando…
The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future
Apomorphine is now recognized as the oldest antiparkinsonian drug on the market. Though still underused, it is increasingly prescribed in Europe for patients with advanced Parkinson’s disease (PD) with motor fluctuations. However, its history is far from being limited to movement disorders. This pap...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995787/ https://www.ncbi.nlm.nih.gov/pubmed/29546602 http://dx.doi.org/10.1007/s40268-018-0230-3 |
_version_ | 1783330669415366656 |
---|---|
author | Auffret, Manon Drapier, Sophie Vérin, Marc |
author_facet | Auffret, Manon Drapier, Sophie Vérin, Marc |
author_sort | Auffret, Manon |
collection | PubMed |
description | Apomorphine is now recognized as the oldest antiparkinsonian drug on the market. Though still underused, it is increasingly prescribed in Europe for patients with advanced Parkinson’s disease (PD) with motor fluctuations. However, its history is far from being limited to movement disorders. This paper traces the history of apomorphine, from its earliest empirical use, to its synthesis, pharmacological development, and numerous indications in human and veterinary medicine, in light of its most recent uses and newest challenges. From shamanic rituals in ancient Egypt and Mesoamerica, to the treatment of erectile dysfunction, from being discarded as a pharmacological tool to becoming an essential antiparkinsonian drug, the path of apomorphine in the therapeutic armamentarium has been tortuous and punctuated by setbacks and groundbreaking discoveries. Throughout history, three main clinical indications stood out: emetic (gastric emptying, respiratory disorders, aversive conditioning), sedative (mental disorders, clinical anesthesia, alcoholism), and antiparkinsonian (fluctuations). New indications may arise in the future, both in PD (palliative care, nonmotor symptoms, withdrawal of oral dopaminergic medication), and outside PD, with promising work in neuroprotection or addiction. |
format | Online Article Text |
id | pubmed-5995787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-59957872018-06-25 The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future Auffret, Manon Drapier, Sophie Vérin, Marc Drugs R D Review Article Apomorphine is now recognized as the oldest antiparkinsonian drug on the market. Though still underused, it is increasingly prescribed in Europe for patients with advanced Parkinson’s disease (PD) with motor fluctuations. However, its history is far from being limited to movement disorders. This paper traces the history of apomorphine, from its earliest empirical use, to its synthesis, pharmacological development, and numerous indications in human and veterinary medicine, in light of its most recent uses and newest challenges. From shamanic rituals in ancient Egypt and Mesoamerica, to the treatment of erectile dysfunction, from being discarded as a pharmacological tool to becoming an essential antiparkinsonian drug, the path of apomorphine in the therapeutic armamentarium has been tortuous and punctuated by setbacks and groundbreaking discoveries. Throughout history, three main clinical indications stood out: emetic (gastric emptying, respiratory disorders, aversive conditioning), sedative (mental disorders, clinical anesthesia, alcoholism), and antiparkinsonian (fluctuations). New indications may arise in the future, both in PD (palliative care, nonmotor symptoms, withdrawal of oral dopaminergic medication), and outside PD, with promising work in neuroprotection or addiction. Springer International Publishing 2018-03-15 2018-06 /pmc/articles/PMC5995787/ /pubmed/29546602 http://dx.doi.org/10.1007/s40268-018-0230-3 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Article Auffret, Manon Drapier, Sophie Vérin, Marc The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future |
title | The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future |
title_full | The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future |
title_fullStr | The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future |
title_full_unstemmed | The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future |
title_short | The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future |
title_sort | many faces of apomorphine: lessons from the past and challenges for the future |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995787/ https://www.ncbi.nlm.nih.gov/pubmed/29546602 http://dx.doi.org/10.1007/s40268-018-0230-3 |
work_keys_str_mv | AT auffretmanon themanyfacesofapomorphinelessonsfromthepastandchallengesforthefuture AT drapiersophie themanyfacesofapomorphinelessonsfromthepastandchallengesforthefuture AT verinmarc themanyfacesofapomorphinelessonsfromthepastandchallengesforthefuture AT auffretmanon manyfacesofapomorphinelessonsfromthepastandchallengesforthefuture AT drapiersophie manyfacesofapomorphinelessonsfromthepastandchallengesforthefuture AT verinmarc manyfacesofapomorphinelessonsfromthepastandchallengesforthefuture |